Pluristem Therapeutics Inc.
MATAM Advanced Technology Park, Building #5, Haifa, Israel 31905
Tel Israel: 972-74-7108600
Tel U.S: 914-512-4109
investor.relations@pluristem.com
www.pluristem.com



INSPIRED by LIFE

COMPANY OVERVIEW

Pluristem Therapeutics is a leading developer of placenta-based cell therapy products. Each patented PLX (PLacental eXpanded) cell product releases a distinct combination of therapeutic proteins in response to signals from tissues that have been damaged by conditions such as inflammation, ischemia, hematological disorders, or exposure to radiation. The cells products require no tissue matching prior to administration, making them cost effective and convenient for use in most medical settings.

The Company's proprietary three-dimensional expansion technology can be used to grow PLX cells in mass quantities with batch-to-batch consistency at Pluristem's FDA, EMA and PMDA-approved, state-of-the-art manufacturing facility. The facility enables Pluristem to control its supply chain, and the purity and potency of its cell products, all at a significantly lower cost of goods.

Pluristem has a robust balance sheet, a strong intellectual property position, and strategic relationships with major institutions around the globe.

05/17

INVESTMENT HIGHLIGHTS

Equity Overview

NASDAQ: PSTI TASE: PSTI/PLTR

Shares Outstanding (05/2017): 96 million
Cash Balance (31/3/2017): $33.1 million
No Debt

Analyst Coverage

H.C. Wainwright & Co.
FBR & Co.
Maxim Group
Jeffries Group
Leader Capital Markets (Israel)
Edison Group

IP Portfolio

Over 100 issued patents and over 110 Pending

Anticipated 12 Months Milestones

Initiate pivotal pre-marketing clinical trials:

- Critical Limb Ischemia (CLI)- U.S., Europe and Japan
- Hip Fracture- U.S. and Europe
- Acute Radiation Syndrome (ARS)

Clinical data readout:

- 170 patients, multinational Phase 2 trial in Intermittent Claudication (IC)
- Incomplete engraftment of hematopoietic cell transplant- open label trial

Business development:

- U.S.- Negotiating contract with government for funding of pivotal study and stockpiling PLX-R18 for ARS
- China- Licensing / JV deal
- Japan- Finalize JV deal with Sosei

Strong Clinical Data

Two completed clinical trials in Critical Limb Ischemia and one in muscle injury have demonstrated significant positive results

CLI advanced trials for marketing approval in $25B Indication

Pluristem plans to initiate two pre-marketing clinical trials in 2017 for PLX-PAD cells in the treatment of Critical Limb Ischemia (CLI) in U.S, Europe and Japan. This program has been accepted to the EU and Japan regulatory pathways which may allow for early marketing approvals. Awarded $8 Million Grant from Europe's Horizon 2020 Program. A binding term sheet was signed with Sosei for investment of $11 million in a JV for the development of CLI in Japan. CLI, a cardiovascular condition in which blockage of blood flow to the limbs can result in gangrene and amputation, is an estimated $25 billion global market.

Pluristem has completed recruitment for a Phase II trial with PLX-PAD for the treatment of Intermittent Claudication (IC), with trial sites located in the U.S., Germany, Israel and South Korea. The Company expects to report data during 2018.

Phase III Femoral Neck Fracture clinical trial

Pluristem plans to initiate a Phase III clinical trial with PLX-PAD cells for the treatment of Femoral Neck Fracture in U.S and Europe. Femoral neck fracture is the most common form of hip fracture with U.S. annual treatment costs estimated to be between $10 to $15 billion, and are expected to rise due to aging population, with mortality rates of up to 36%.

ARS pivotal study via FDA animal rule

The U.S. National Institutes of Health funded and conducted a pilot study designed to assess safety and efficacy of PLX-R18 following IM injection into irradiated and non-irradiated NHPs. Efficacy measures included survival and level of bone marrow function. Pilot study results showed improvement in survival rates in NHPs treated with PLX-R18 (85%) compared to untreated groups (50%). PLX-R18 cells showed safety in non-irradiated NHPs, indicating no requirement to determine levels of radiation exposure prior to administration. Study demonstrated a trend towards enhanced neutrophil and lymphocyte recovery.

Data will inform a pivotal trial that could support marketing authorization under the FDA's Animal Rule regulatory pathway.

Collaboration agreement with the Fukushima Medical University to study PLX-R18 for the treatment of other components of ARS (GI, Lung and Skin), and for morbidities following radiotherapy in cancer patients.

PLX-R18 for Hematologic Indications

Phase I trial in incomplete engraftment of transplanted hematopoietic cells. 30 patients, open-label trial which allows for interim data analysis. Preclinical data show that PLX-R18 triggers the recovery of the bone marrow's ability to produce blood cells, suggesting that this cell product could potentially treat a broad range of hematological indications.